Nortran Completes Phase II Clinical Trial.VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--Sept. 16, 1998-- Nortran(VSE See DOS/VSE. VSE - Virtual Storage Extended :NRT.) (OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. :NTRDF) Nortran Pharmaceuticals Inc., NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). BB:NTRDF, VSE:NRT (the "Company") announced today the completion of all treatments for the phase II clinical trials of its local anaesthetic product, RSD921. A total of 110 patients and volunteers have now received doses ranging from 0.05 percent - 0.25 percent of RSD921. This trial was conducted with the Company's development partner, the Chemical Company of Malaysia Berhad ("CCM"), at the University Hospital, University of Malaya The University of Malaya (or Universiti Malaya in Malay; commonly abbreviated as UM) is the oldest university in Malaysia, and is situated on a 750 acre (3.0 km²) campus in southwest Kuala Lumpur, the capital city. . The final reports on the trial results are expected by mid October. The data will provide a foundation for further licensing discussions on RSD921 with pharmaceutical companies in other areas of the world, and will be the basis for phase III clinical trials. Nortran Pharmaceuticals is a drug discovery company focusing on pathology targeted small molecules. The Company recently announced a partnership with F. Hoffmann La Roche covering part of its antiarrhythmic antiarrhythmic /an·ti·ar·rhyth·mic/ (-ah-rith´mik) 1. preventing or alleviating cardiac arrhythmias. 2. an agent that so acts. an·ti·ar·rhyth·mic adj. development program in the area of atrial fibrillation. Nortran's current drugs in development target life- threatening arrhythmias of the heart, pain management, sexual dysfunction and acute cough. ON BEHALF OF THE BOARD Michael J.A. Walker, Ph.D., Chairman WARNING: THE COMPANY RELIES ON LITIGATION PROTECTION FOR "FORWARD-LOOKING" STATEMENTS. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion